Casirivimab

Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms[1][2].

Product Specifications

CAS Number

[2415933-42-3]

Product Name Alternative

REGN10933

UNSPSC

12352203

Target

SARS-CoV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/casirivimab.html

Purity

95.0

Solubility

10 mM in DMSO

Smiles

[Casirivimab]

Molecular Weight

(145.24 kDa)

References & Citations

[1]Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD) : National Institute of Child Health and Human Development; 2006–. Casirivimab. 2022 May 15. |[2]Lee Tatham, et al. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case. Microbiol Spectr. 2024 Aug 6;12 (8) :e0391623.